Delivery Order SPE2DR25D1103-SPE2DR26FF042
- Not listed
- On January 14, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,184.60 to AmerisourceBergen Drug Corp for XDEMVY 0.25% DROP 10ML, a pharmaceutical product to be delivered to Conshohocken, Pennsylvania by February 5, 2026. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp (subsidiary of parent company Cencora, Inc.) on January 8, 2026, for the supply of XDEMVY 0.25% DROP 10ML, a pharmaceutical product. This competitively awarded, non-set-aside contract has a ceiling value of $1,184.60 and is scheduled for completion by January 30, 2026. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with firm fixed-price terms. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XDEMVY 0.25% Drop 10ML, a pharmaceutical product. This competitively awarded, firm fixed-price delivery order has a ceiling value of $1,223.59 and is scheduled for completion by August 25, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under a larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for pharmaceutical products valued at $1,184.60. The award is for XDEMVY 0.25% Drop 10ML and is structured as a firm fixed price delivery order with an ultimate completion date of November 24, 2025. This non-competitive award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle...
- This delivery order, valued at $1,184.60, was awarded to AmerisourceBergen Drug Corp (a subsidiary of parent company Cencora, Inc.) by the Defense Logistics Agency on January 16, 2026, for the supply of XDEMVY 0.25% Drop 10ML pharmaceutical product. The award is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. Performance will be completed by February 9, 2026, at the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for pharmaceutical supplies totaling $1,184.60 with a firm fixed price. The specific product is XDEMVY 0.25% Drop in 10ml format, which will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 2, 2026. This is a competitively awarded contract with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,184.60 to AmerisourceBergen Drug Corp on January 15, 2026, for the supply of XDEMVY 0.25% Drop 10ML, a pharmaceutical product. The contract utilizes firm fixed-price pricing and is classified as a child delivery order under a larger indefinite delivery contract. Performance will be completed by February 6, 2026, at the contractor's facility in Conshohocken, Pennsylvania. This award was made through competitive procedures with...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $3,670.77 to AmerisourceBergen Drug Corp on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is for XDEMVY 0.25% DROP 10ML pharmaceutical product and will be performed in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. The award involved no set-aside designation and was competitively awarded to the vendor. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of XDEMVY 0.25% DROP 10ML pharmaceutical product. This firm fixed-price delivery order has a ceiling value of $1,223.59 and is scheduled for completion by October 16, 2025. The contract is being performed in Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters, and does not utilize a set-aside designation. As a child contract, this...
- The Defense Logistics Agency awarded a $1,223.59 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of XDEMVY 0.25% Drop in a 10 mL formulation, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FF042Delivery Order
On February 2, 2026, the Defense Logistics Agency awarded a delivery order valued at $1,184.60 to AmerisourceBergen Drug Corp for XDEMVY 0.25% Drop 10ML, a pharmaceutical product. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of February 24, 2026. This award was made on a competitive, non-set-aside basis and will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate operations. The delivery order is issued under AmerisourceBergen Drug Corp's parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2031, serving as the underlying vehicle for this task order. AmerisourceBergen is a major pharmaceutical distributor providing critical medical supply chain support to the Department of Defense healthcare system. The company supplies an extensive portfolio of pharmaceutical products and medical commodities to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. This particular delivery order represents a routine pharmaceutical procurement under the broader DLA medical supply contract, consistent with the company's ongoing role as a primary vendor for federal military healthcare pharmaceutical needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 2/1/26 |